Pioglitazone improves cardiovascular risk markers for patients with diabetes
Caroline Barranco
This article has no abstract so we have provided the first paragraph of the full text.
Results of the Pioneer study suggest that pioglitazone has anti-inflammatory and antiatherosclerotic effects, independent of glycemic control, which might be the direct result of peroxisome proliferative activated receptor gamma activation.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
